PET CT Re-Planning NSCLC (4DCT-PET)

Prospective Study of CT and PET Imaging During a Course of Radical Radiotherapy to Determine the Dosimetric Benefits of Re-Planning in Non-Small Cell Lung Cancer

Status

Completed

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT03403127

Enrollment

Registered

2018-01-18

Start date

2008-05-20

Completion date

2020-04-28

Last updated

2020-08-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Lung Cancer, Non-Small Cell Lung Cancer

Brief summary

This study will see whether the addition of more frequent planning CTs during the course of radiation, and of Positron Emission Tomography (PET), a diagnostic test similar to CT, prior to and during a course of radiation may provide information that could potentially be used during the treatment to improve the initial radiation plan.

Interventions

DIAGNOSTIC_TESTPET/CT Scans

PET Imaging requires the use of an investigational drug, a radioactively-labelled sugar called 18F-Fluorodeoxyglucose (FDG). FDG is glucose labelled with a radioactive fluorine atom. It is given by intravenous injection and is particularly absorbed by cancer cells. The radioactive signal given off by the FDG can then be detected by the PET scanner providing an image of the cancer (or tumour).

Study design

Allocation

Intervention model

SINGLE_GROUP

Primary purpose

DIAGNOSTIC

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Age equal to or more than 18 years old * Patients with NSCLC consenting for radiotherapy to the primary tumor and / or mediastinal / hilar lymph nodes. Prescription doses should be 60Gy or higher. * Chemo-RT patients of any stage of NSCLC * Patients with a measurable tumor on CT scan. * Patients who are able to lie supine for two consecutive 25 minutes sessions.

Exclusion criteria

* Trimodality patients who will have surgery within 2 months post RT * Previous radiotherapy to intended treatment volumes. * Patients with recurrent disease * Active malignancy other than lung cancer * Pregnancy * Failure to provide written informed consent

Design outcomes

Primary

Measure	Time frame	Description
GTV volumes	2 weeks post RT treatment	The ratio of the GTV volumes defined using 4D CT (GTV4DCT) planning scans is a prognostic parameter for NSCLC.
GTV Volumes	4 weeks post RT Treatment	The ratio of the GTV volumes defined using FDG PET (GTVPET) planning scans

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026